Develop tadekinig-alpha to treat inflammation
Employees: 11-50
Total raised: $50.89M
Founded date: 2010
Investors 1
| Date | Name | Website |
| - | VI Partner... | vipartners... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 03.08.2026 | - | $30M | - |
| 14.01.2016 | Series B | $20.89M | - |
Mentions in press and media 6
| Date | Title | Description |
| 03.08.2026 | AB2 Bio Receives $30 Million From Nippon Shinyaku For U.S. Tadekinig Alfa Rights, With Up To $600 Million In Milestones And Royalties | AB2 Bio has received a $30 million payment after Nippon Shinyaku exercised its option for exclusive U.S. commercialization rights to Tadekinig alfa in a rare pediatric hyperinflammatory disease. The agreement covers Tadekinig alfa for Prima... |
| 31.07.2026 | AB2 Bio receives USD 30 million from Nippon Shinyaku | Primary monogenic interleukin-18-driven hyperinflammatory syndrome is caused by mutations in the NLRC4 and XIAP genes. Patients develop sharply elevated levels of free interleukin-18 (IL-18), a signalling protein that drives systemic infla... |
| 27.01.2025 | AB2 Bio signs USD 600 million agreement with Nippon Shinyaku | AB2 Bio has entered into an option and licensing agreement with Nippon Shinyaku Co. Ltd., a leading Japanese pharmaceutical company with extensive experience in marketing rare disease therapeutics in the U.S. Under the terms of the agreeme... |
| 03.03.2020 | AB2 Bio prepares market entry of its lead product | |
| 03.03.2020 | AB2 Bio prepares market entry of its lead product | Lausanne-based AB2 Bio Ltd is specialized in developing innovative therapies for the treatment of severe systemic autoinflammatory diseases, including rare diseases with high unmet medical needs. The company is conducting a pivotal Phase 3 ... |
| 14.01.2016 | AB2 Bio Ltd raises CHF 21 million in Series B financing round |